112 related articles for article (PubMed ID: 20653501)
1. Protein-misfolding diseases and the paradigm of proteomics-based therapeutic targets.
Singh OV
Expert Rev Proteomics; 2010 Aug; 7(4):463-4. PubMed ID: 20653501
[No Abstract] [Full Text] [Related]
2. Spotlight focuses on protein-misfolding therapies.
Ratner M
Nat Biotechnol; 2009 Oct; 27(10):874. PubMed ID: 19816426
[No Abstract] [Full Text] [Related]
3. Proteomics uncovering possible key players in F508del-CFTR processing and trafficking.
Gomes-Alves P; Penque D
Expert Rev Proteomics; 2010 Aug; 7(4):487-94. PubMed ID: 20653505
[TBL] [Abstract][Full Text] [Related]
4. Molecular chaperones as therapeutic targets to counteract proteostasis defects.
Cattaneo M; Dominici R; Cardano M; Diaferia G; Rovida E; Biunno I
J Cell Physiol; 2012 Mar; 227(3):1226-34. PubMed ID: 21618531
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of aggregate formation as therapeutic target in protein misfolding diseases: effect of tetracycline and trehalose.
Sirangelo I; Irace G
Expert Opin Ther Targets; 2010 Dec; 14(12):1311-21. PubMed ID: 21058920
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in targeting protein misfolding diseases.
Denny RA; Gavrin LK; Saiah E
Bioorg Med Chem Lett; 2013 Apr; 23(7):1935-44. PubMed ID: 23454013
[TBL] [Abstract][Full Text] [Related]
7. Identification of anti-infective targets through comparative proteomics.
Burchmore R
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):163-5. PubMed ID: 16597196
[No Abstract] [Full Text] [Related]
8. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins.
Naiki H; Nagai Y
J Biochem; 2009 Dec; 146(6):751-6. PubMed ID: 19643812
[TBL] [Abstract][Full Text] [Related]
9. Schistosomes--proteomics studies for potential novel vaccines and drug targets.
DeMarco R; Verjovski-Almeida S
Drug Discov Today; 2009 May; 14(9-10):472-8. PubMed ID: 19429506
[TBL] [Abstract][Full Text] [Related]
10. Proteins of the Hedgehog signaling pathway as therapeutic targets against cancer.
Nehmé R; Mus-Veteau I
Expert Rev Proteomics; 2010 Aug; 7(4):601-12. PubMed ID: 20653513
[TBL] [Abstract][Full Text] [Related]
11. [Ligandomics--a tool for the development of targeted treatments].
Porkka K; Laakkonen P
Duodecim; 2002; 118(11):1185-92. PubMed ID: 12239852
[No Abstract] [Full Text] [Related]
12. Neurodegenerative disease: Phosphatase inhibitor prevents protein-misfolding diseases.
Crunkhorn S
Nat Rev Drug Discov; 2015 Jun; 14(6):386. PubMed ID: 25976385
[No Abstract] [Full Text] [Related]
13. Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding.
Ho L; Pasinetti GM
Expert Rev Proteomics; 2010 Aug; 7(4):579-89. PubMed ID: 20653511
[TBL] [Abstract][Full Text] [Related]
14. The Fourth International Peptide Symposium: discovery to drugs: the peptide pipeline.
Benson H; Toth I
Biopolymers; 2008; 90(5):588. PubMed ID: 18821571
[No Abstract] [Full Text] [Related]
15. A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases.
Baranczak A; Kelly JW
Curr Opin Chem Biol; 2016 Jun; 32():10-21. PubMed ID: 26859714
[TBL] [Abstract][Full Text] [Related]
16. A chemogenomic approach to drug discovery: focus on cardiovascular diseases.
Cases M; Mestres J
Drug Discov Today; 2009 May; 14(9-10):479-85. PubMed ID: 19429507
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule modulation of cellular chaperones to treat protein misfolding disorders.
Sloan LA; Fillmore MC; Churcher I
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):666-81. PubMed ID: 19736625
[TBL] [Abstract][Full Text] [Related]
18. Application of proteomics in biotechnology--microbial proteomics.
Josic D; Kovac S
Biotechnol J; 2008 Apr; 3(4):496-509. PubMed ID: 18320565
[TBL] [Abstract][Full Text] [Related]
19. Nanoimaging for protein misfolding diseases.
Lyubchenko YL; Kim BH; Krasnoslobodtsev AV; Yu J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(5):526-43. PubMed ID: 20665728
[TBL] [Abstract][Full Text] [Related]
20. The critical need for cancer biometrics: quantitative, reproducible measures of cancer to define response to therapy.
Lotze MT
Curr Opin Investig Drugs; 2003 Jun; 4(6):649-51. PubMed ID: 12901221
[No Abstract] [Full Text] [Related]
[Next] [New Search]
